Therapeutic Yoga: A feasible complementary approach for glycemic control in individuals with impaired fasting glucose and elevated HbA1c

IF 1.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Gitika Bhasin , Rucha S. Dafale , Annapoorna K. , Shobha U. Kamath , Divya Matlani , Raju Rana , Mukhyaprana M. Prabhu , Akhilesh K. Pandey , Sahana Shetty , Lavya Shetty , Vasanthalaxmi K. , Manjula S.D.
{"title":"Therapeutic Yoga: A feasible complementary approach for glycemic control in individuals with impaired fasting glucose and elevated HbA1c","authors":"Gitika Bhasin ,&nbsp;Rucha S. Dafale ,&nbsp;Annapoorna K. ,&nbsp;Shobha U. Kamath ,&nbsp;Divya Matlani ,&nbsp;Raju Rana ,&nbsp;Mukhyaprana M. Prabhu ,&nbsp;Akhilesh K. Pandey ,&nbsp;Sahana Shetty ,&nbsp;Lavya Shetty ,&nbsp;Vasanthalaxmi K. ,&nbsp;Manjula S.D.","doi":"10.1016/j.conctc.2025.101493","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Impaired Fasting Glucose (IFG) with elevated glycated hemoglobin (HbA1c) is a key precursor to type 2 diabetes mellitus (T2DM). Although asymptomatic, IFG significantly raises the risk of developing T2DM and cardiovascular complications, emphasizing the need for early intervention. The Therapeutic Yoga Module (TYM) was designed to offer a feasible and effective remedy for improving glycemic control.</div></div><div><h3>Methods</h3><div>The TYM was designed by combining different yoga practices including asanas, pranayama, relaxation, and dhyana. After validating the module, a feasibility study was carried out on 12 individuals. Subsequently, the preliminary impact was assessed on 29 individuals (intervention group = 14 and control group = 15) with IFG. The study evaluated practicality, participant acceptance, and changes in Fasting Blood Glucose (FBG) and HbA1c levels over 12 weeks.</div></div><div><h3>Results</h3><div>The TYM achieved a content validity index (CVI) of 0.75, with 15 out of 20 practices deemed effective by the expert panel. The Intra-Class Correlation (ICC) coefficient of 0.864 indicated strong reliability. Feasibility testing revealed high participant acceptance, with an average attendance rate of 84.9 %. The intervention group showed significant improvements in FBG (from 108.79 mg/dL to 91.00 mg/dL, P &lt; 0.001) and HbA1c (from 6.00 % to 5.73 %, P &lt; 0.001), compared to the control group, which had more modest improvements. The analysis of covariance (ANCOVA) analysis confirmed that these improvements were primarily attributable to TYM.</div></div><div><h3>Conclusion</h3><div>Preliminary findings suggest that TYM may be a promising complementary intervention for individuals with IFG or at risk of T2DM.</div></div><div><h3>Trial registration</h3><div>Clinical Trials Registry - India (CTRI); Registration number: CTRI/2022/04/042307; Registration Date: April 29, 2022.</div></div>","PeriodicalId":37937,"journal":{"name":"Contemporary Clinical Trials Communications","volume":"45 ","pages":"Article 101493"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary Clinical Trials Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451865425000675","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Impaired Fasting Glucose (IFG) with elevated glycated hemoglobin (HbA1c) is a key precursor to type 2 diabetes mellitus (T2DM). Although asymptomatic, IFG significantly raises the risk of developing T2DM and cardiovascular complications, emphasizing the need for early intervention. The Therapeutic Yoga Module (TYM) was designed to offer a feasible and effective remedy for improving glycemic control.

Methods

The TYM was designed by combining different yoga practices including asanas, pranayama, relaxation, and dhyana. After validating the module, a feasibility study was carried out on 12 individuals. Subsequently, the preliminary impact was assessed on 29 individuals (intervention group = 14 and control group = 15) with IFG. The study evaluated practicality, participant acceptance, and changes in Fasting Blood Glucose (FBG) and HbA1c levels over 12 weeks.

Results

The TYM achieved a content validity index (CVI) of 0.75, with 15 out of 20 practices deemed effective by the expert panel. The Intra-Class Correlation (ICC) coefficient of 0.864 indicated strong reliability. Feasibility testing revealed high participant acceptance, with an average attendance rate of 84.9 %. The intervention group showed significant improvements in FBG (from 108.79 mg/dL to 91.00 mg/dL, P < 0.001) and HbA1c (from 6.00 % to 5.73 %, P < 0.001), compared to the control group, which had more modest improvements. The analysis of covariance (ANCOVA) analysis confirmed that these improvements were primarily attributable to TYM.

Conclusion

Preliminary findings suggest that TYM may be a promising complementary intervention for individuals with IFG or at risk of T2DM.

Trial registration

Clinical Trials Registry - India (CTRI); Registration number: CTRI/2022/04/042307; Registration Date: April 29, 2022.
治疗性瑜伽:对空腹血糖受损和HbA1c升高的个体进行血糖控制的一种可行的补充方法
背景:空腹血糖受损(IFG)伴糖化血红蛋白(HbA1c)升高是2型糖尿病(T2DM)的关键前兆。虽然无症状,但IFG显著增加了发生2型糖尿病和心血管并发症的风险,强调了早期干预的必要性。治疗瑜伽模块(TYM)旨在为改善血糖控制提供可行有效的补救措施。方法结合体式、调息、放松和禅坐等不同瑜伽练习,设计TYM。在验证了该模块后,对12个人进行了可行性研究。随后,对29人(干预组14人,对照组15人)使用IFG进行初步影响评估。该研究评估了实用性、参与者接受度以及12周内空腹血糖(FBG)和HbA1c水平的变化。结果TYM的内容效度指数(CVI)为0.75,专家小组认为20个实践中有15个是有效的。类内相关系数(ICC)为0.864,信度较强。可行性测试显示参与者的接受度很高,平均出勤率为84.9%。干预组空腹血糖有显著改善(从108.79 mg/dL降至91.00 mg/dL, P <;0.001)和HbA1c(从6.00%降至5.73%,P <;0.001),与对照组相比,对照组的改善更为温和。协方差分析(ANCOVA)证实这些改善主要归因于TYM。结论:初步研究结果表明,TYM可能是一种有希望的补充干预,对于有IFG或有T2DM风险的个体。印度临床试验注册中心(CTRI);注册号:CTRI/2022/04/042307;报名日期:2022年4月29日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
2.70
自引率
6.70%
发文量
146
审稿时长
20 weeks
期刊介绍: Contemporary Clinical Trials Communications is an international peer reviewed open access journal that publishes articles pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from a wide range of disciplines including medicine, life science, pharmaceutical science, biostatistics, epidemiology, computer science, management science, behavioral science, and bioethics. Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions. Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信